Baidu
map

Cell Rep:BMP4基因疗法:逆转2型糖尿病的新希望

2017-08-25 Heather_z727 来宝网

在萨尔格学院的一项研究中,经过蛋白质BMP4基因治疗之后,即使摄入高能量饮食,体重没有增加,胰岛素敏感性也没有增加,完整的研究报告发表于《细胞》杂志中。



BMP4基因疗法预防小鼠体重增加和胰岛素抵抗】在萨尔格学院的一项研究中,经过蛋白质BMP4基因治疗之后,即使摄入高能量饮食,体重没有增加,胰岛素敏感性也没有增加,完整的研究报告发表于《细胞》杂志中。

在研究报告中,研究人员指出,“通过增加BMP4,我们可以增加代谢率,但是我们只在最初精瘦小鼠体内看到这一条件,而肥胖老鼠则证明了BMP4的阻力,这也是一个重要的发现。”

关于BMP4好处的研究最近经常看到,其中包括调节体内白色,棕色脂肪,白色脂肪细胞负责存储和释放脂肪,棕色脂肪细胞燃烧脂肪,产生热量,在胎儿发育的过程中,BMP4也具有重要功能。

在此次研究中,研究人员给老鼠喂食高脂肪,能源丰富的饮食,与此同时,也为它们注射一种携带BMP4的无害病毒,在最初瘦老鼠中,研究人员看到白色脂肪新陈代谢变得越来越活跃,而棕色脂肪变成了“白色”,这对于小鼠的代谢健康具有更加正面的影响。因为体重增加以及无法抵御胰岛素的抵抗都是2型糖尿病的风险标志。

而BMP4基因治疗可以使体重维持正常,免受能量摄入增加导致的胰岛素抵抗。超重的动物有着更高水平的BMP4蛋白质,也有高水平的拮抗剂,阻止脂肪的BMP4信号。换句话说,他们抵抗BMP4对褐色脂肪细胞的积极作用。

目前的研究还处于基础阶段,进一步的研究会确定BMP4对脂肪和胰岛素抵抗的作用,开启治疗2型糖尿病的新方向。

原始出处:

Jenny M. Hoffmann et al, BMP4 Gene Therapy in Mature Mice Reduces BAT Activation but Protects from Obesity by Browning Subcutaneous Adipose Tissue, Cell Reports (2017). DOI: 10.1016/j.celrep.2017.07.020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634004, encodeId=9f04163400435, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Aug 25 18:40:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960403, encodeId=5cae1960403c4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jun 01 14:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969952, encodeId=4e4c196995269, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Jan 17 21:40:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870142, encodeId=ce3d18e0142b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 08 19:40:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237013, encodeId=6c3623e0134b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 25 15:40:53 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 HNYYM
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634004, encodeId=9f04163400435, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Aug 25 18:40:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960403, encodeId=5cae1960403c4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jun 01 14:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969952, encodeId=4e4c196995269, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Jan 17 21:40:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870142, encodeId=ce3d18e0142b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 08 19:40:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237013, encodeId=6c3623e0134b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 25 15:40:53 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2018-06-01 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634004, encodeId=9f04163400435, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Aug 25 18:40:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960403, encodeId=5cae1960403c4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jun 01 14:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969952, encodeId=4e4c196995269, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Jan 17 21:40:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870142, encodeId=ce3d18e0142b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 08 19:40:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237013, encodeId=6c3623e0134b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 25 15:40:53 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2018-01-17 珙桐
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634004, encodeId=9f04163400435, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Aug 25 18:40:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960403, encodeId=5cae1960403c4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jun 01 14:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969952, encodeId=4e4c196995269, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Jan 17 21:40:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870142, encodeId=ce3d18e0142b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 08 19:40:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237013, encodeId=6c3623e0134b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 25 15:40:53 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1634004, encodeId=9f04163400435, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Aug 25 18:40:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960403, encodeId=5cae1960403c4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jun 01 14:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969952, encodeId=4e4c196995269, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Jan 17 21:40:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870142, encodeId=ce3d18e0142b2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 08 19:40:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237013, encodeId=6c3623e0134b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 25 15:40:53 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Diabet Med:自我管理导向教育方案可改善2型糖尿病的血糖控制

糖尿病是目前比较常见的疾病种类之一,随着人们生活水的不断提高,其发病率也随之增高。2017年8月,发表在《Diabet Med》的一项随机、多中心研究调查了MEDIAS 2 BSC教育方案对非强化胰岛素治疗的2型糖尿病患者的影响。

J Hypertens:糖尿病患者要降低MACE风险的目标收缩压是多少?

由此可见,将收缩压控制在120至140毫米汞柱之间可能有助于降低糖尿病患者的心血管风险。将收缩压控制在120毫米汞柱以内并不会降低其心血管的风险。

Ann Inter Med:“连续葡萄糖监测法”有望逆转2型糖尿病,血糖接近正常!

8月22日,发表于《内科医学年鉴》上的研究报告指出,成人2型糖尿病患者每天注射胰岛素,接收多个随机连续葡萄糖监测(CGM)可以改善血糖控制和常规治疗效果。

解析2017年AACE/ACE糖尿病综合管理共识:强化降脂是大势所趋

今年内,美国临床内分泌医师协会(AACE)与美国内分泌学会(ACE)先后发布两项指南性文件,分别为“2型糖尿病综合管理共识声明”与“血脂管理和心血管病预防指南”。两项指南性文件均对糖尿病患者的血脂管理做出了新的推荐建议,其中最值得关注的是为2型糖尿病患者的降胆固醇治疗提出了更为严格的控制目标。

Circulation:多学科讨论:二甲双胍能预防糖尿病患者冠脉钙化风险?

糖尿病是冠心病的等危症。尽管对冠心病风险因素进行强化管理,但仍然存在相当多的糖尿病相关的冠心病风险,这表明这些靶向冠心病的临床干预措施在确定的糖尿病患者中的益处存在局限性。2017年7月,《Circulation》的一项研究调查了长期使用二甲双胍和生活方式改善对于糖尿病冠脉钙化的影响。

Sci Trans Med:常见的肥胖和糖尿病药物可以降低脑压力

一项由英国伯明翰大学(University of Birmingham)发表在《科学转化医学》(Science Translational Medicine)上的一项研究揭示:一种常用于治疗肥胖或II型糖尿病患者的药物GLP-1受体激动剂药物可以降低大脑压力。

Baidu
map
Baidu
map
Baidu
map